Alcohol Dependence
Conditions
Keywords
alcohol dependence, alcohol abuse, drinking, alcohol
Brief summary
This study would like to test whether the combination of ondansetron and olanzapine will be superior to placebo at decreasing self-reported heavy drinking among early onset alcoholics.
Detailed description
Target population: We will enroll male and female who meet DSM IV criteria for alcohol dependence and who are currently drinking equal or more than 21 alcohol units/week for women and equal or more than 28 alcohol units/week for men in the 7 day period prior to enrollment. This is a double-blind placebo-controlled study. Eligible subjects will be randomized to ondansetron (4 ug/kg) and olanzapine (9, 18, 36 ug/kg) vs placebo. All subjects will participate in a 9 week regimen of weekly BBCET and outpatient medication treatment.
Interventions
DRUGOndansetron
ondansetron (4 μg/kg b.i.d.)
DRUGOlanzapine
olanzapine (9, 18, and 36 μg/kg)
DRUGPlacebo
placebo
Sponsors
University of Virginia
Study design
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Males and females who have given written informed consent * Aged 18 years and above and weighing ≥40 kg and ≤140 kg * Drinking on average ≥21 and ≥28 drinks/week for women and men, respectively, in the 7-day period prior to enrollment * DSM-IV-R diagnosis of alcohol dependence * Good physical health as determined by a complete physical examination, electrocardiogram (EKG) within normal limits and laboratory screening tests within acceptable range * Negative pregnancy test at intake. * Literate in English and able to read, understand, and complete the rating scales and questionnaires accurately, follow instructions, and make use of the behavioral treatments * Willing to participate in behavioral treatments for alcoholism * Answer an advertisement in the newspaper/radio/television, and express a wish to stop drinking * Provide evidence of stable residence in the last month prior to enrollment in the study, and have no plans to move in the next three months
Exclusion criteria
* Any current axis I DSM-IV psychiatric disorder other than alcohol or nicotine dependence that warrants treatment or would preclude safe participation in the protocol * Severe alcohol withdrawal symptoms that, in the physician's opinion, require inpatient treatment * Serious medical comorbidity requiring medical intervention or close supervision, or any condition that can interfere with the receipt of ondansetron or olanzapine * Severe or life-threatening adverse reactions to the ondansetron or olanzapine medications in the past or during this clinical trial * Female subjects who are pregnant, lactating, or not adhering to an acceptable form of contraception at any time during the study * Received inpatient or outpatient treatment for alcohol dependence within the last 30 days * Significant medical illness (including hypertension) as determined by history and/or complete physical examination. * Gross neurological disease * Mental retardation * Pyrexia of unknown origin * Diagnosis or suspicion of Alzheimer's disease * Clinically significant abnormalities on the EKG that will preclude safe participation * Recent (last 3 months) history of ischemic heart disease or myocardial infarction. * Current infective hepatitis as evidenced by clinical manifestations. If hepatitis is suspected, a hepatitis antibody/antigen screen will be done. * Participation in a clinical study within the last 30 days * Elevation of liver enzymes * History of any severe or life-threatening reaction to olanzapine or ondansetron * Past or current history of seizures disorder * Past or current history of diabetes * Being treated with any medication with potential for clinically significant interactions with alcohol or olanzapine and/or ondansetron. These include:, serotonin antagonists (e.g., ritanserin or buspirone), dopamine antagonists (e.g., haloperidol), or compounds with actions similar to disulfiram (Antabuse®). * Pending imprisonment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The combination of ondansetron and olanzapine will be safe and superior to placebo at decreasing self-reported heavy drinking among early-onset alcoholics. | Throughout the study |
Secondary
| Measure | Time frame |
|---|---|
| The combination of ondansetron and olanzapine will be superior to placebo at reducing the psychosocial consequences of drinking. | Throughout the study |
Countries
United States
Outcome results
None listed